ArticleInfection and immunity2014
Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB.
Article in Infection and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 54 citations in OpenAlex.
- Impact of Light-Activated Nanocomposite with Erythrosine B onAntibiotics (Basel, Switzerland) · 2025Article
- A comprehensive review of pathology and treatment of staphylococcus aureus osteomyelitis.Clinical and experimental medicine · 2025Review
- Toxin-neutralizing Abs are associated with improved T cell function following recovery from Staphylococcus aureus infection.JCI insight · 2024Article
- Staphylococcal mastitis in dairy cows.Frontiers in veterinary science · 2024Review
- Molecular Characteristics and Pathogenicity ofInternational journal of molecular sciences · 2023Review
- Microbes and the fate of neutrophils.Immunological reviews · 2023Review
- Staphylococcal trafficking and infection-from 'nose to gut' and back.FEMS microbiology reviews · 2022Review
- Adoptive Transfer of Serum Samples From Children With Invasive Staphylococcal Infection and Protection Against Staphylococcus aureus Sepsis.The Journal of infectious diseases · 2021Article
- Dissecting the Human Response toFrontiers in immunology · 2021Article
- Evasion of Immunological Memory byFrontiers in immunology · 2021Review
- Identification of a domain critical forThe Journal of biological chemistry · 2020Article
- Targeting leukocidin-mediated immune evasion protects mice from Staphylococcus aureus bacteremia.The Journal of experimental medicine · 2020Article
- Review
- Unbiased Identification of Immunogenic Staphylococcus aureus Leukotoxin B-Cell Epitopes.Infection and immunity · 2020Article
- Exploiting species specificity to understand the tropism of a human-specific toxin.Science advances · 2020Article
- Antivirulence Strategies for the Treatment ofFrontiers in microbiology · 2020Review
- Molecular Epidemiology of Invasive Staphylococcus aureus Infections and Concordance with Colonization Isolates.The Journal of pediatrics · 2019Article
- Host-Pathogen Interactions in Gram-Positive Bacterial Pneumonia.Clinical microbiology reviews · 2019Review
- Rational Design of Toxoid Vaccine Candidates forToxins · 2019Article
- Serologic Detection of Antibodies Targeting the Leukocidin LukAB Strongly Predicts Staphylococcus aureus in Children With Invasive Infection.Journal of the Pediatric Infectious Diseases Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Despite the importance of Staphylococcus aureus as a common invasive bacterial pathogen, the humoral response to infection remains inadequately defined, particularly in children. The purpose of this study was to assess the humoral response to extracellular staphylococcal virulence factors, including the bicomponent leukotoxins, which are critical for the cytotoxicity of S. aureus toward human neutrophils. Children with culture-proven S. aureus infection were prospectively enrolled and stratified by disease type. Fifty-three children were enrolled in the study, of which 90% had invasive disease. Serum samples were obtained during the acute (within 48 h) and convalescent (4 to 6 weeks postinfection) phases, at which point both IgG titers against S. aureus exotoxins were determined, and the functionality of the generated antibodies was evaluated. Molecular characterization of clinical isolates was also performed. We observed a marked rise in antibody titer from acute-phase to convalescent-phase sera for LukAB, the most recently described S. aureus bicomponent leukotoxin. LukAB production by the isolates was strongly correlated with cytotoxicity in vitro, and sera containing anti-LukAB antibodies potently neutralized cytotoxicity. Antibodies to S. aureus antigens were detectable in healthy pediatric controls but at much lower titers than in sera from infected subjects. The discovery of a high-titer, neutralizing antibody response to LukAB during invasive infections suggests that this toxin is produced in vivo and that it elicits a functional humoral response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.